thalidomide has been researched along with Hypertension, Portal in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In an open-label pilot study, 20 abstinent patients with stable alcoholic cirrhosis and oesophageal varices were recruited; 12 patients completed haemodynamic measurements before and after treatment with oxpentifylline (pentoxifylline) 1800 mg (n=6) or thalidomide 200 mg (n=6) daily for 2 weeks." | 9.11 | A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. ( Austin, AS; Clarke, D; Freeman, JG; Mahida, YR; Ryder, SD, 2004) |
| "Portal hypertension was induced by partial ligation of the portal vein (PVL)." | 5.29 | Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. ( Cadelina, G; Groszmann, RJ; Lopez-Talavera, JC; Merrill, W; Olchowski, J, 1996) |
| "In an open-label pilot study, 20 abstinent patients with stable alcoholic cirrhosis and oesophageal varices were recruited; 12 patients completed haemodynamic measurements before and after treatment with oxpentifylline (pentoxifylline) 1800 mg (n=6) or thalidomide 200 mg (n=6) daily for 2 weeks." | 5.11 | A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. ( Austin, AS; Clarke, D; Freeman, JG; Mahida, YR; Ryder, SD, 2004) |
| "Thalidomide seems to be a promising agent that might bring about beneficial changes to the disarrangements of peripheral, hepatic, splanchnic and collateral systems in cirrhosis." | 1.43 | Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats. ( Alan, L; Hsieh, SL; Hsieh, YC; Huang, CC; Lee, KC; Lee, SD; Li, TH; Lin, HC; Tsai, CY; Yang, YY, 2016) |
| "Portal hypertension is a common complication of liver cirrhosis and significantly increases mortality and morbidity." | 1.42 | Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure. ( Korshunov, VA; Maluccio, MA; Skill, NJ; Theodorakis, NG; Wang, YN, 2015) |
| "Portal hypertension was induced by partial ligation of the portal vein (PVL)." | 1.29 | Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. ( Cadelina, G; Groszmann, RJ; Lopez-Talavera, JC; Merrill, W; Olchowski, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Theodorakis, NG | 1 |
| Wang, YN | 1 |
| Korshunov, VA | 1 |
| Maluccio, MA | 1 |
| Skill, NJ | 1 |
| Li, TH | 1 |
| Huang, CC | 1 |
| Yang, YY | 1 |
| Lee, KC | 1 |
| Hsieh, SL | 1 |
| Hsieh, YC | 1 |
| Alan, L | 1 |
| Lin, HC | 1 |
| Lee, SD | 1 |
| Tsai, CY | 1 |
| Jimenez-Saenz, M | 1 |
| Romero-Vazquez, J | 1 |
| Caunedo-Alvarez, A | 1 |
| Maldonado-Perez, B | 1 |
| Gutierrez, JM | 1 |
| Austin, AS | 1 |
| Mahida, YR | 1 |
| Clarke, D | 1 |
| Ryder, SD | 1 |
| Freeman, JG | 1 |
| Lopez-Talavera, JC | 1 |
| Cadelina, G | 1 |
| Olchowski, J | 1 |
| Merrill, W | 1 |
| Groszmann, RJ | 1 |
1 trial available for thalidomide and Hypertension, Portal
| Article | Year |
|---|---|
A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Enzyme Inhibitors; Female; H | 2004 |
4 other studies available for thalidomide and Hypertension, Portal
| Article | Year |
|---|---|
Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.
Topics: Animals; Antihypertensive Agents; Aorta, Abdominal; Arterial Pressure; Biomarkers; Blood Flow Veloci | 2015 |
Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats.
Topics: Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Human Umbilical Vein Endothelial Cel | 2016 |
Beneficial effects and reversion of vascular lesions by thalidomide in a patient with bleeding portal hypertensive enteropathy.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Compassionate Use Trials; Female; Gastrointestinal Hemorrha | 2010 |
Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats.
Topics: Animals; Blood Pressure; Disease Models, Animal; Hemodynamics; Hypertension, Portal; Male; Nitric Ox | 1996 |